States / New Hampshire / SB 465
SB 465 Failed
classifying xylazine as a schedule III controlled drug.
Introduced
In Committee
Floor
Crossed Over
Passed
Enacted
Apr 23, 2026 · House
Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 P. 55
Apr 15, 2026 · House
Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)
Apr 15, 2026 · House
Minority Committee Report: Ought to Pass
Apr 8, 2026 · House
Executive Session: 04/14/2026 01:00 pm GP 153
Apr 1, 2026 · House
Full Committee Work Session: 04/07/2026 01:00 pm GP 153
Mar 18, 2026 · House
Public Hearing: 03/31/2026 01:30 pm GP 153
Mar 16, 2026 · House
Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture HJ 8 P. 114
Feb 24, 2026 · Senate
Committee Amendment # 2026-0842s, AA, VV; 03/05/2026; SJ 5
Feb 24, 2026 · Senate
Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5
Feb 20, 2026 · Senate
Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8
Feb 5, 2026 · Senate
Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A
Nov 21, 2025 · Senate
Introduced 01/07/2026 and Referred to Judiciary; SJ 1